Robert Ilesan

Research Topic: Artificial Intelligence

Background and Research Interest

Robert Radu Ileșan is a researcher in the Swiss MAM group, enrolled in two programs: Clinical Research and Biomedical Engineering, at the University of Basel. At the age of 30 he obtained the recognition as Specialist for oral and maxillofacial surgery in Romania, which means that he successfully finished studying human medicine, dentistry followed by the 5 years of trainee as a surgeon. As a human medicine student he was granted the Erasmus scholarship at University Hospital Aachen (RWTH), the largest multidisciplinary hospital in Europe. It was here, where he decided to dedicated his career to the pursuit of the improvement of healthcare systems. On these grounds he finished a master in healthcare management in 2012-2013 and after he passed the specialist exam (2016) he was appointed as advisor to the State Secretary for Health (2017), in Bucharest. This experience offered him a vivid understanding about challenges faced by healthcare systems in developing countries and the realization that "problem solving" starts with "problem recognizing" and the importance of transparency throughout the process. His initial focus was on neurodegenerative diseases, one of the most expensive medical issue in the world. In a world with a population that is growing and getting older, the only solution which he identified was Artificial Intelligence (AI).This research is ongoing and will have as result a medical device prototype for neurodegenerative assessment that unites medical data with AI, gaming, and biosensors. His current focus is on AI based workflows for patient-specific treatments in craniomaxillofacial surgery (CMF). The idea is to offer design optimization done by surgeons for surgeons in collaboration with biomedical experts and industry partners. As he is still practicing as a surgeon one of his tasks in our research group is to offer a direct link between biomedical engineering and the operating theatre.

The ability to design and fabricate patient-specific implants at the point of care will help deliver the implants at a reasonable cost by eliminating the need for outsourcing, as well as reducing the lead times to enable fast response in case of complications.  

All these self-intelligent solutions should lead to higher standards in CMF surgery.

Robert Ilesan

Robert Ilesan

Gewerbestrasse 14
4123 Allschwil, Switzerland